The PCR-based OncoMate MSI Dx Analysis System can now identify patients with MSI-H solid tumors who may be eligible for pembrolizumab.
|Videos|September 11, 2013
Penny Daugherty on Discussing Patients' Genetics
Author(s)Penny Daugherty, RN, MS, OCN
Penny Daugherty, RN, MS, OCN, Southeastern Gynecologic Oncology, explains how nurses in her practice discuss genetics and genomics with patients.
Advertisement
Penny Daugherty, RN, MS, OCN, Southeastern Gynecologic Oncology, explains how nurses in her practice discuss genetics and genomics with patients.
Daugherty says that information on genetics counseling is distributed to patients. If the patient wishes to discuss the contents of the packet, the nurses make themselves available.
Genetics counselors are also present at support group meetings to answer any questions that patients may have, Daugherty says. Genetics presenters will educate nurses on genetics and genomics so that nurses can provide better care to patients.
Advertisement
Related to this article
The FDA set a June 25, 2027, target action date for gedatolisib plus fulvestrant in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer.
TP53 Comutations, Long-Term Toxicity, and Sunvozertinib Access Shape EGFR+ NSCLC Treatment Decisions
Faculty at an OncLive Scientific Interchange and Workshop discussed factors that help inform treatment selection in advanced EGFR-mutated NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
Mo-Rez Responses Span B7-H4 Expression Levels in Platinum-Resistant Ovarian Cancer in BEHOLD-1 Biomarker Analysis
2
Genomic Testing, Toxicity, and Sequencing Shape Treatment Decisions in Advanced Prostate Cancer
3
Dr Natsuhara on Treatment Advances and Research Considerations in TNBC
4
Dr Nunnery on Chemo De-Escalation, Ovarian Function Suppression, and Toxicity Management in Breast Cancer
5